Govt To Slash MRP Of 3 Anti-Cancer Drugs

New Delhi: After custom duty exemption and a reduction in GST rates, the National Pharmaceutical Pricing Authority (NPPA) has now directed the drug manufacturers to reduce the MRP on three anti-cancer medications, the Ministry of Chemicals and Fertilisers said on Tuesday.

The NPPA in an office memorandum dated October 28 directed “the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab”.

“This is in line with the Government’s commitment to ensure the availability of drugs at affordable prices,” the ministry added.